Trials / Completed
CompletedNCT02002832
A Clinical Trial of Lurasidone in Treatment of Schizophrenia
A Randomized, Double-blind, Double-dummy, Parallel-group and Multicenter Study to Investigate Lurasidone in Treatment of Schizophrenia Compared With Risperidone
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 388 (actual)
- Sponsor
- Sumitomo Pharma (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and to compare with risperidone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lurasidone tablets | Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo) |
| DRUG | Risperidone tablets | Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo) |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2015-04-01
- Completion
- 2015-11-01
- First posted
- 2013-12-06
- Last updated
- 2019-11-15
- Results posted
- 2019-04-01
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02002832. Inclusion in this directory is not an endorsement.